|
|
|
|
Assessing the Real-World Effectiveness and
Clinical Efficacy of 8198 Patients Receiving
Elbasvir/Grazoprevir for the Treatment of HCV Infection
|
|
|
AASLD 2019 Nov 8-11 Boston
Jennifer R. Kramer1,2; Amy Puenpatom3; Barbara A. Haber3; Peggy Hwang3; Xian Yu1,2; Fasiha Kanwal1,2
1Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX;
2Department of Medicine, Baylor College of Medicine, Houston, TX; 3Merck & Co., Inc., Kenilworth, NJ
|
|
|
|
|
|
|